ondansetron has been researched along with arginine vasopressin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Barreca, T; Cataldi, A; Cianciosi, P; Corsini, G; Franceschini, R; Garibaldi, A; Rolandi, E | 1 |
| Caffarri, G; Capretti, L; Chiodera, P; Coiro, V; Giuliani, N; Magotti, MG; Volpi, R | 1 |
| Wilkens, EP; Yates, BJ | 1 |
| Cataldo, S; Chiodera, P; Coiro, V; Maffei, ML; Minelli, R; Vacca, P; Volpi, R; Volta, E | 1 |
| Charalambous, M; Elliott, J; Foth, S; Henze, L; Kenward, H; Meller, S; Pelligand, L; Twele, F; Volk, HA | 1 |
1 review(s) available for ondansetron and arginine vasopressin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for ondansetron and arginine vasopressin
| Article | Year |
|---|---|
Ondansetron in dogs with nausea associated with vestibular disease: A double-blinded, randomized placebo-controlled crossover study.
Topics: Animals; Antiemetics; Arginine Vasopressin; Cross-Over Studies; Dog Diseases; Dogs; Double-Blind Method; Metoclopramide; Nausea; Ondansetron; Vestibular Diseases; Vomiting | 2022 |
6 other study(ies) available for ondansetron and arginine vasopressin
| Article | Year |
|---|---|
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Effect of the 5-HT3 receptor antagonist ondansetron on plasma AVP secretion: a study in cancer patients.
Topics: Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Arginine Vasopressin; Breast Neoplasms; Female; Humans; Middle Aged; Ondansetron; Serotonin Antagonists | 1996 |
5-HT3 serotonergic receptor mediation of hypoglycemia-induced arginine-vasopressin but not oxytocin secretion in normal men.
Topics: Adult; Arginine Vasopressin; Humans; Hypoglycemia; Insulin; Kinetics; Male; Ondansetron; Oxytocin; Placebos; Receptors, Serotonin; Serotonin Antagonists | 1998 |
Pretreatment with ondansetron blunts plasma vasopressin increases associated with morphine administration in ferrets.
Topics: Animals; Antiemetics; Arginine Vasopressin; Ferrets; Male; Morphine; Nausea; Ondansetron; Postoperative Nausea and Vomiting | 2005 |
Effect of serotonergic system on AVP secretion induced by physical exercise.
Topics: Adult; Arginine Vasopressin; Blood Glucose; Buspirone; Exercise; Hemodynamics; Humans; Male; Ondansetron; Osmolar Concentration; Serotonin; Serotonin Receptor Agonists; Sumatriptan; Young Adult | 2010 |